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From the Editor

Dare to Compare
Introduction
As part of the American Recovery and
Reinvestment Act (ARRA), Congress mandated
that the Institute of Medicine (IOM) establish a
list of Comparative Effectiveness Research (CER)
priorities by June 30, 2009. ARRA authorized a
$1.1 billion down payment to support national
CER efforts. Of the total funds, $400 million is to
be released by the Secretary of Health and Human
Services, and is likely to be targeted towards topics
consistent with the IOM list. Another $400 million
is to be released by the National Institutes of
Health (NIH), and the remaining $300 million is
to be dispersed by Agency for Healthcare Research
and Quality (AHRQ). At the time of this writing,
there were two Congressional proposals to sustain
national CER efforts. In a recent interview about
health reform, President Obama supported CER in
saying “There’s always going to be an asymmetry
of information between patient and provider.
Part of what I think government can do is to be
an honest broker in assessing and evaluating
treatment options.”1
What is Comparative Effectiveness Research?
The IOM Committee defined CER as “the
generation and synthesis of evidence that compares
the benefits and harms of alternative methods
to prevent, diagnose, treat and monitor a clinical
condition, or to improve the delivery of care. The
purpose of CER is to assist consumers, clinicians,
purchasers, and policy makers to make informed
decisions that will improve health care at both the
individual and population levels.” 2,3
The report states six characteristics of CER:
1. CER has the objective of directly informing
a specific clinical decision from the patient
perspective or a health policy decision from the
population perspective.
2. CER compares at least two alternative
interventions, each with the potential to be
“best practice.”
3. CER describes results at the population and
subgroup levels.

4. CER measures outcomes - both benefits and
harms - that are important to patients.
5. CER employs methods and data sources
appropriate for the decision of interest.
6. CER is conducted in settings that are similar to
those in which the intervention will be used in practice.
The premise of CER is simple: we should invest
in the medical treatments that are proven to be
effective in defined patient populations in realworld practice settings. CER can be conducted
using a variety of approaches, including
randomized trials, prospective observational
studies, database analyses, and systematic reviews
- all methods of population health research. CER
is conducted in settings that are similar to those in
which the intervention will be used in practice.
The IOM Committee created a list of 100
recommended priorities, through a structured
review of potential topics identified through a
national survey. The full list is available at:
www.iom.edu/cerpriorities. Priorities in the top
quartile include comparing the effectiveness of
treatment strategies for: atrial fibrillation; hearing
loss; dementia; prostate cancer; dental caries;
ADHD and obesity in children; prevention of
falls in older adults; chronic care management
programs; biologics for inflammatory diseases;
screening, prophylaxis and treatment programs
for methicillin resistant staphylococcus aureus
(MRSA) and healthcare acquired infection; and
genetic and biomarker testing for certain cancers. A
broad array of interventions was recommended to
evaluate these priorities, including systems of care;
pharmacological treatment; behavioral treatment;
prevention; procedures; testing, monitoring, and
evaluation; devices; standard of care; alternative
treatment; provider-patient relationships; and
treatment pathways.
CER provides clinicians and health plans with
the ability to compare treatments to each other
(or to usual care) rather than to placebo, and to
understand the effectiveness of treatments in defined
populations. Though manufacturers will continue

placebo-controlled trials in order to meet FDA
requirements, CER will provide real-world evidence
on competing treatments via head to head trials,
observational studies, and database analyses (for
example, patient registries or claims datasets). CER
will also elucidate the effectiveness of treatments in
groups typically underrepresented in clinical trials,
such as children, the elderly, and minority groups.
Role of Economic Analysis in CER
Applied health economic analysis is an important
component of CER because it reveals which
treatments yield maximal value. Applied health
economics involves weighing effectiveness and costs
of competing treatment interventions, typically via
formal cost effectiveness analyses. First published
nearly two decades ago, best practices for cost
effectiveness analysis have stood the test of time with a significant increase in published studies in
recent years.4 Opponents to including cost in CER
fear that it may impede patients’ access to expensive
care; however, cost effectiveness analysis often
recommends the use of more expensive treatments if
they produce better outcomes. Thus, cost effectiveness
does not necessarily translate to cost savings, but
may instead mean better results for the dollars spent.
This type of analysis becomes increasingly important
when competing treatments are equally effective, or
have marginal differences in effectiveness.5
Jefferson School of Population Health: Committed
to Developing the CER Workforce
The IOM Committee report noted that the career
pathways for CER are not clear, and there is a lack
of federally funded graduate and post-graduate
training programs aimed at grooming investigators in
population health research. The committee predicted
a “substantial need” for experts in the disciplines of
CER, including outcomes research, observational data
analysis, cost effectiveness, statistical modeling, and
epidemiology.2
The Jefferson School of Population Health anticipates
this growing national need for CER researchers.
Through our existing two-year postdoctoral
fellowships in applied health economics and
outcomes research, JSPH has trained more than 30
professionals in the methods of CER during the past
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15 years. This past year, we doubled the number
of available fellowship slots from 2 to 4. Moving
ahead, we are committed to further building the
CER workforce with graduate-level degrees centered
on CER methods, particularly a Master of Science
degree in Applied Health Economics (presently
in development). This degree will focus on the
methods of cost effectiveness analysis, observational
studies, health utility and quality of life outcomes
research, and economic modeling. It will be the
first in the US to emphasize important population

health interventions such as screening programs,
vaccinations, occupational and physical therapy,
surgical techniques, dietary modification and exercise
regimens. We believe that the CER workforce of the
future will be called upon to evaluate this broad array
of population health interventions in addition to the
traditional evaluation of new drugs and devices.
As we move forward in shaping this degree,
we welcome your views and opinions. With
your input, we hope to build a strong and

sustainable program which develops national
leaders in CER. 
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